{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Talari NK"],"funding":["China Scholarship Council","NIDDK NIH HHS","National Institute of Diabetes and Digestive and Kidney Diseases","National Institutes of Health"],"pagination":["109709"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11059128"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["27(5)"],"pubmed_abstract":["Recent studies demonstrate that liver secretory proteins, also known as hepatokines, regulate normal development, obesity, and simple steatosis to non-alcoholic steatohepatitis (NASH) progression. Using a panel of ∼100 diverse inbred strains of mice and a cohort of bariatric surgery patients, we found that one such hepatokine, inter-trypsin inhibitor heavy chain 3 (ITIH3), was progressively lower in severe non-alcoholic fatty liver disease (NAFLD) disease states highlighting an inverse relationship between <i>Itih3</i>/<i>ITIH3</i> expression and NAFLD severity. Follow-up animal and cell culture models demonstrated that hepatic ITIH3 overexpression lowered liver triglyceride and lipid droplet accumulation, respectively. Conversely, ITIH3 knockdown in mice increased the liver triglyceride i"],"journal":["iScience"],"pubmed_title":["Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and <i>de novo</i> lipogenesis."],"pmcid":["PMC11059128"],"funding_grant_id":["R00DK120875","R00 DK120875"],"pubmed_authors":["Talari NK","Peterfy M","Rahman AP","Chella Krishnan K","Pihlajamaki J","Pajukanta P","Mattam U","Kaminska D","Sotomayor-Rodriguez I"],"additional_accession":[]},"is_claimable":false,"name":"Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and <i>de novo</i> lipogenesis.","description":"Recent studies demonstrate that liver secretory proteins, also known as hepatokines, regulate normal development, obesity, and simple steatosis to non-alcoholic steatohepatitis (NASH) progression. Using a panel of ∼100 diverse inbred strains of mice and a cohort of bariatric surgery patients, we found that one such hepatokine, inter-trypsin inhibitor heavy chain 3 (ITIH3), was progressively lower in severe non-alcoholic fatty liver disease (NAFLD) disease states highlighting an inverse relationship between <i>Itih3</i>/<i>ITIH3</i> expression and NAFLD severity. Follow-up animal and cell culture models demonstrated that hepatic ITIH3 overexpression lowered liver triglyceride and lipid droplet accumulation, respectively. Conversely, ITIH3 knockdown in mice increased the liver triglyceride i","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T23:50:02.933Z","creation":"2026-05-23T03:08:11.432Z"},"accession":"S-EPMC11059128","cross_references":{"pubmed":["38689636"],"doi":["10.1016/j.isci.2024.109709"]}}